CONFERENCE DAY ONE

8:00 am Digital Networking Room Opens

8:25 am Chair’s Opening Remarks

Developing Innovative Combination Strategies to Unlock Novel Applications of Hippo- Targeted Drugs

8:30 am Per Aspera Ad Astra: The Potential of Hippo Pathway inhibition as a Mono- & Combination Therapy Concept

9:00 am Panel Discussion: Advancing Hippo Pathway Combination Strategies: Exploring Current & Future Cross-Pathway Opportunities

  • Chenglong Li Professor, University of Florida
  • Wanjin Hong Chief Business Development Officer, Biomedical Research Council (BMRC) at A*STAR
  • Srinivas Vindo Saladi Assistant Professor, University of Toledo, College of Medicine and Life Sciences
  • Satu Juhila Project Leader, Orion Pharma

9:45 am Morning Break & Virtual Networking

Tackling Resistance Mechanisms Driven by the Hippo Pathway to Effectively Develop Combination Strategies Against MAPK & EGFR Cancers

10:30 am Determining New Roles of the Hippo Pathway in Driving Cancer Formation, Progression & Adaptive Resistance to Inform Combination Strategies

11:00 am Exploring Resistance Mechanisms in MAPK-Addicted Cancers: YAP Upregulation, Immune Suppression, & Innovative Combination Strategies for Hippo Pathway Targeted Drugs

  • Kari Kurppa Principal Investigator & Academy Research Fellow, University of Turku

11:30 am Drug Persistence Versus Drug Resistance to KRAS G12C Inhibitors & implications for YAP/TAZ Targeted Drugs

  • Alessia Mira Senior Postdoc, Molecular Biotechnology Center, University of Torino

12:00 pm Lunch Break & Virtual Networking

Developing Innovative Drugs Against YAP & TEAD Through Cutting-Edge Discovery Platforms to Hit the Pathway at Multiple Nodes

Chair: Melanie Frigault, Consultant, Translational Medicine, Vincerx Pharma

1:00 pm QUANTROseq®, a Transcriptomic-Based Drug Discovery Platform to Identify Inhibitors & Degraders of Transcription Factors & Cell Signaling Regulators

  • Arianna Sabò Head of Research & Discovery, QUANTRO Therapeutics

1:30 pm Advancing the Discovery & Development of a Novel YAP Degrader Against Liver Cancer

2:00 pm Discovery & Development of a Novel Covalent TEAD Inhibitor with Exceptional Anti-Cancer Activity & Druggability

  • Shirley Guo Director of Biology, BridGene Biosciences Inc.

2:30 pm Afternoon Break & Virtual Networking

Tackling Late Discovery & Early Pre-Clinical Bottlenecks to Accelerate Your Hippo Drug into the Clinic

3:15 pm Presenting a Novel Pan TEAD Inhibitor to Treat Hippo Pathway Dysregulated Tumors

3:45 pm Panel Discussion: Optimizing the Discovery & Development of Effective Small Molecule Drugs Against TEAD to Expedite Translation to the Clinic

4:30 pm Targeting the Hippo Pathway Through GPCRs to Cure Inflammatory, Oncological & Autoimmune Conditions

  • Zhi Liang Chu Founder, Chief Executive Officer & Chief scientific officer, Crossignal Therapeutics

5:00 pm Chair’s Closing Remarks & End of Day One